A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors

Laura W. Goff, Roger B. Cohen, Jordan D. Berlin, Filippo De Braud, Andrej Lyshchik, Cristina Noberasco, Francesco Bertolini, M. Carpentieri, C. G. Stampino, A. Daniele Abbattista, Erjan Wang, Hossein Borghaei

Research output: Contribution to journalArticle

Abstract

Purpose: Objectives of this dose-finding study were to determine the MTD and recommended phase II dose (RP2D) of the first-in-class anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962, and assess safety and antitumor activity in patients with advanced solid tumors. Experimental Design: This open-label, multicenter study was based on a 3+3 design. PF-03446962 was administered biweekly by intravenous infusion, at doses ranging from 0.5 to 15 mg/kg. Results: Forty-four patients received treatment with PF-03446962. Dose-limiting toxicities observed during dose escalation included grade 3 increased amylase, grade 3/4 increased lipase, and grade 3/4 thrombocytopenia. The MTD was determined to be 10 mg/kg. The RP2D was set at 7 mg/kg for patients with advanced solid tumors, based on the observed safety, pharmacokinetics, and antitumor activity. The most-frequent treatment-related, all-grade adverse events included thrombocytopenia (20.5%), fatigue (15.9%), and nausea, increased amylase, and increased lipase (each 11.4%). Treatment-related telangiectasia was noted in 7% of patients, suggesting in vivo inhibition of the ALK-1 pathway. None of the deaths was deemed to be treatmentrelated. Three (6.8%) patients with advanced hepatocellular carcinoma, renal cell carcinoma, or non-small cell lung cancer achieved a partial response, and 12 (27.3%) patients had stable disease, across dose levels. Contrast-enhanced ultrasound analysis of tumor vascularity showed reduction in tumor perfusion in 2 patients with stable disease following treatment with PF-03446962. Conclusions: The clinical activity demonstrated in this study points to PF-03446962 as a novel approach to antiangiogenic therapy, with manageable safety profile and single-agent, antitumor activity in patients with advanced solid tumors.

Original languageEnglish
Pages (from-to)2146-2154
Number of pages9
JournalClinical Cancer Research
Volume22
Issue number9
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Activin Receptors
Monoclonal Antibodies
Neoplasms
Amylases
Lipase
Safety
Therapeutics
Telangiectasis
PF-03446962
Renal Cell Carcinoma
Intravenous Infusions
Non-Small Cell Lung Carcinoma
Thrombocytopenia
Antineoplastic Agents
Nausea
Multicenter Studies
Fatigue
Hepatocellular Carcinoma
Research Design
Pharmacokinetics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. / Goff, Laura W.; Cohen, Roger B.; Berlin, Jordan D.; De Braud, Filippo; Lyshchik, Andrej; Noberasco, Cristina; Bertolini, Francesco; Carpentieri, M.; Stampino, C. G.; Abbattista, A. Daniele; Wang, Erjan; Borghaei, Hossein.

In: Clinical Cancer Research, Vol. 22, No. 9, 01.05.2016, p. 2146-2154.

Research output: Contribution to journalArticle

Goff, LW, Cohen, RB, Berlin, JD, De Braud, F, Lyshchik, A, Noberasco, C, Bertolini, F, Carpentieri, M, Stampino, CG, Abbattista, AD, Wang, E & Borghaei, H 2016, 'A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors', Clinical Cancer Research, vol. 22, no. 9, pp. 2146-2154. https://doi.org/10.1158/1078-0432.CCR-15-1622
Goff, Laura W. ; Cohen, Roger B. ; Berlin, Jordan D. ; De Braud, Filippo ; Lyshchik, Andrej ; Noberasco, Cristina ; Bertolini, Francesco ; Carpentieri, M. ; Stampino, C. G. ; Abbattista, A. Daniele ; Wang, Erjan ; Borghaei, Hossein. / A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 9. pp. 2146-2154.
@article{d5f3b2db451649779b740a32d04a57aa,
title = "A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors",
abstract = "Purpose: Objectives of this dose-finding study were to determine the MTD and recommended phase II dose (RP2D) of the first-in-class anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962, and assess safety and antitumor activity in patients with advanced solid tumors. Experimental Design: This open-label, multicenter study was based on a 3+3 design. PF-03446962 was administered biweekly by intravenous infusion, at doses ranging from 0.5 to 15 mg/kg. Results: Forty-four patients received treatment with PF-03446962. Dose-limiting toxicities observed during dose escalation included grade 3 increased amylase, grade 3/4 increased lipase, and grade 3/4 thrombocytopenia. The MTD was determined to be 10 mg/kg. The RP2D was set at 7 mg/kg for patients with advanced solid tumors, based on the observed safety, pharmacokinetics, and antitumor activity. The most-frequent treatment-related, all-grade adverse events included thrombocytopenia (20.5{\%}), fatigue (15.9{\%}), and nausea, increased amylase, and increased lipase (each 11.4{\%}). Treatment-related telangiectasia was noted in 7{\%} of patients, suggesting in vivo inhibition of the ALK-1 pathway. None of the deaths was deemed to be treatmentrelated. Three (6.8{\%}) patients with advanced hepatocellular carcinoma, renal cell carcinoma, or non-small cell lung cancer achieved a partial response, and 12 (27.3{\%}) patients had stable disease, across dose levels. Contrast-enhanced ultrasound analysis of tumor vascularity showed reduction in tumor perfusion in 2 patients with stable disease following treatment with PF-03446962. Conclusions: The clinical activity demonstrated in this study points to PF-03446962 as a novel approach to antiangiogenic therapy, with manageable safety profile and single-agent, antitumor activity in patients with advanced solid tumors.",
author = "Goff, {Laura W.} and Cohen, {Roger B.} and Berlin, {Jordan D.} and {De Braud}, Filippo and Andrej Lyshchik and Cristina Noberasco and Francesco Bertolini and M. Carpentieri and Stampino, {C. G.} and Abbattista, {A. Daniele} and Erjan Wang and Hossein Borghaei",
year = "2016",
month = "5",
day = "1",
doi = "10.1158/1078-0432.CCR-15-1622",
language = "English",
volume = "22",
pages = "2146--2154",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors

AU - Goff, Laura W.

AU - Cohen, Roger B.

AU - Berlin, Jordan D.

AU - De Braud, Filippo

AU - Lyshchik, Andrej

AU - Noberasco, Cristina

AU - Bertolini, Francesco

AU - Carpentieri, M.

AU - Stampino, C. G.

AU - Abbattista, A. Daniele

AU - Wang, Erjan

AU - Borghaei, Hossein

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Purpose: Objectives of this dose-finding study were to determine the MTD and recommended phase II dose (RP2D) of the first-in-class anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962, and assess safety and antitumor activity in patients with advanced solid tumors. Experimental Design: This open-label, multicenter study was based on a 3+3 design. PF-03446962 was administered biweekly by intravenous infusion, at doses ranging from 0.5 to 15 mg/kg. Results: Forty-four patients received treatment with PF-03446962. Dose-limiting toxicities observed during dose escalation included grade 3 increased amylase, grade 3/4 increased lipase, and grade 3/4 thrombocytopenia. The MTD was determined to be 10 mg/kg. The RP2D was set at 7 mg/kg for patients with advanced solid tumors, based on the observed safety, pharmacokinetics, and antitumor activity. The most-frequent treatment-related, all-grade adverse events included thrombocytopenia (20.5%), fatigue (15.9%), and nausea, increased amylase, and increased lipase (each 11.4%). Treatment-related telangiectasia was noted in 7% of patients, suggesting in vivo inhibition of the ALK-1 pathway. None of the deaths was deemed to be treatmentrelated. Three (6.8%) patients with advanced hepatocellular carcinoma, renal cell carcinoma, or non-small cell lung cancer achieved a partial response, and 12 (27.3%) patients had stable disease, across dose levels. Contrast-enhanced ultrasound analysis of tumor vascularity showed reduction in tumor perfusion in 2 patients with stable disease following treatment with PF-03446962. Conclusions: The clinical activity demonstrated in this study points to PF-03446962 as a novel approach to antiangiogenic therapy, with manageable safety profile and single-agent, antitumor activity in patients with advanced solid tumors.

AB - Purpose: Objectives of this dose-finding study were to determine the MTD and recommended phase II dose (RP2D) of the first-in-class anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962, and assess safety and antitumor activity in patients with advanced solid tumors. Experimental Design: This open-label, multicenter study was based on a 3+3 design. PF-03446962 was administered biweekly by intravenous infusion, at doses ranging from 0.5 to 15 mg/kg. Results: Forty-four patients received treatment with PF-03446962. Dose-limiting toxicities observed during dose escalation included grade 3 increased amylase, grade 3/4 increased lipase, and grade 3/4 thrombocytopenia. The MTD was determined to be 10 mg/kg. The RP2D was set at 7 mg/kg for patients with advanced solid tumors, based on the observed safety, pharmacokinetics, and antitumor activity. The most-frequent treatment-related, all-grade adverse events included thrombocytopenia (20.5%), fatigue (15.9%), and nausea, increased amylase, and increased lipase (each 11.4%). Treatment-related telangiectasia was noted in 7% of patients, suggesting in vivo inhibition of the ALK-1 pathway. None of the deaths was deemed to be treatmentrelated. Three (6.8%) patients with advanced hepatocellular carcinoma, renal cell carcinoma, or non-small cell lung cancer achieved a partial response, and 12 (27.3%) patients had stable disease, across dose levels. Contrast-enhanced ultrasound analysis of tumor vascularity showed reduction in tumor perfusion in 2 patients with stable disease following treatment with PF-03446962. Conclusions: The clinical activity demonstrated in this study points to PF-03446962 as a novel approach to antiangiogenic therapy, with manageable safety profile and single-agent, antitumor activity in patients with advanced solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=84968866156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968866156&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-1622

DO - 10.1158/1078-0432.CCR-15-1622

M3 - Article

VL - 22

SP - 2146

EP - 2154

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -